273 related articles for article (PubMed ID: 10515895)
1. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
2. The use of Shiga-like toxin 1 in cancer therapy.
Gariépy J
Crit Rev Oncol Hematol; 2001; 39(1-2):99-106. PubMed ID: 11418306
[TBL] [Abstract][Full Text] [Related]
3. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
4. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice.
LaCasse EC; Saleh MT; Patterson B; Minden MD; Gariépy J
Blood; 1996 Sep; 88(5):1561-7. PubMed ID: 8781410
[TBL] [Abstract][Full Text] [Related]
5. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction.
Szczepek AJ; Seeberger K; Wizniak J; Mant MJ; Belch AR; Pilarski LM
Blood; 1998 Oct; 92(8):2844-55. PubMed ID: 9763569
[TBL] [Abstract][Full Text] [Related]
6. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Widmer L; Pichert G; Jost LM; Stahel RA
Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
[TBL] [Abstract][Full Text] [Related]
7. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
8. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
9. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
Gazitt Y; Reading CC; Hoffman R; Wickrema A; Vesole DH; Jagannath S; Condino J; Lee B; Barlogie B; Tricot G
Blood; 1995 Jul; 86(1):381-9. PubMed ID: 7540887
[TBL] [Abstract][Full Text] [Related]
10. A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.
Louis SA; Zapf R; Clarke E; Thomas TE; Sutherland HJ
Cytotherapy; 2001; 3(6):489-504. PubMed ID: 11953033
[TBL] [Abstract][Full Text] [Related]
11. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation.
Thirukkumaran CM; Luider JM; Stewart DA; Cheng T; Lupichuk SM; Nodwell MJ; Russell JA; Auer IA; Morris DG
Blood; 2003 Jul; 102(1):377-87. PubMed ID: 12637331
[TBL] [Abstract][Full Text] [Related]
12. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.
Cohen A; Madrid-Marina V; Estrov Z; Freedman MH; Lingwood CA; Dosch HM
Int Immunol; 1990; 2(1):1-8. PubMed ID: 1965141
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Yang H; Robinson SN; Nieto Y; Jones RJ; Gocke CD; Lu J; Giralt SA; Jones RB; Decker WK; Xing D; Steiner D; Champlin RE; McMannis JD; Ng J; Thomas MW; Shah N; Andersson BS; Parmar S; Shpall EJ
Cancer Res; 2011 Jul; 71(14):5040-9. PubMed ID: 21646477
[TBL] [Abstract][Full Text] [Related]
14. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
15. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections.
Altès A; Sierra J; Esteve J; Martín-Henao G; Marín P; Sureda A; Briones J; Martino R; Villamor N; Colomer D; Carreras E; Garcia J; Brunet S; Montserrat E
Exp Hematol; 2002 Jul; 30(7):824-30. PubMed ID: 12135682
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry.
Conway EJ; Wen J; Feng Y; Mo A; Huang WT; Keever-Taylor CA; Hari P; Vesole DH; Chang CC
Arch Pathol Lab Med; 2009 Oct; 133(10):1594-9. PubMed ID: 19792049
[TBL] [Abstract][Full Text] [Related]
17. Purging of myeloma cells using all-trans retinoic acid in a mouse model.
Henry JM; Morley AA; Sykes PJ
Exp Hematol; 2001 Mar; 29(3):315-21. PubMed ID: 11274759
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
19. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.
Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S
Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
